Suggestions
Andreas Bergthaler
Principal Investigator at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Andreas Bergthaler is a prominent scientist and academic, currently serving as a Professor of Molecular Immunology at the Medical University of Vienna (MedUni Wien) and as an Adjunct Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. His research primarily focuses on the interplay between inflammation and metabolism, particularly in the context of viral infections and diseases such as cachexia, which is often associated with chronic illnesses like cancer and autoimmune disorders.
Education and Career Path
- Veterinary Medicine: Bergthaler studied veterinary medicine at the University of Veterinary Medicine in Vienna.
- Graduate Studies: He completed his doctoral studies at the Institute of Experimental Immunology at the University of Zurich under the supervision of notable figures such as Hans Hengartner and Nobel laureate Rolf Zinkernagel.
- Postdoctoral Research: His postdoctoral work included positions at the University of Geneva and the Institute for Systems Biology in Seattle.
In 2011, Bergthaler established his independent research group at CeMM, focusing on the molecular mechanisms underlying viral infections and their impact on immune responses. His laboratory employs advanced methodologies, including next-generation sequencing and systems biology approaches, to explore these complex interactions.
Research Interests
Bergthaler's research encompasses several key areas:
- Inflammation and Metabolism: Investigating how inflammatory processes affect metabolism across different organs.
- Viral Infections: Understanding how viruses manipulate host immune responses, with significant work on SARS-CoV-2 mutational dynamics.
- Public Health Applications: Developing pathogen surveillance systems to inform public health strategies.
He has received multiple accolades for his contributions to science, including an ERC Starting Grant and various awards from virology societies. Additionally, Bergthaler is a co-founder of Hookipa Pharma, a company focused on developing immunotherapies for infectious diseases and cancer.
Current Roles
As of January 2022, he transitioned to MedUni Wien while maintaining his affiliation with CeMM. His dual role allows him to continue contributing to both academic research and practical applications in immunology.
Bergthaler's work is characterized by a collaborative approach that bridges various disciplines within biomedical science, aiming to enhance our understanding of immune responses in health and disease.




